Spectral AI: 3 Key Takeaways for Long-Term Investors
Recurring software leases, not device sales, are what could turn Spectral AI’s research base into lasting margins, and the article leaves that transition unproven.
By The Motley Fool Team –
Key Points
-
Spectral AI began manufacturing its first 30 DeepView AI systems.
-
The company requested a $2,750 per patient Medicare reimbursement add-on payment.
-
Full-year 2026 research revenue guidance was updated to approximately $13 million.
On its third-quarter 2026 earnings call, held on Nov. 10, 2026, Spectral AI (MDAI -20.61%) announced progress in transitioning from a research organization into a commercial medical technology enterprise. The shift from government-funded research toward recurring commercial software revenue could shape the company’s long-term results. Three things management said stand out.
1. Manufacturing Begins for First 30 DeepView AI Systems
Management launched production of its initial 30 DeepView AI units, an artificial intelligence wound assessment platform, to support government-backed hospital placements. This deployment aims to build the clinical foundation for commercial sales targeted in 2026.
To that end, during this quarter, we began manufacturing the first 30 DeepView AI systems for BARDA supported deployments at US burn centers.
— Vincent Stanley Capone, Chief Executive Officer
2. Spectral AI Pursues Medicare NTAP Reimbursement for Hospitals
Spectral AI applied for a New Technology Add-on Payment, or NTAP, through the Centers for Medicare and Medicaid Services, known as CMS. Approval would provide hospitals with an additional $2,750 per patient in Medicare reimbursement, which could lower economic barriers to adoption for health systems.
Early in the third quarter, we submitted a new technology add on payment or NTAP application to the Centers for Medicare and Medicaid Services for our Deep View system.
— Vincent Stanley Capone, Chief Executive Officer
3. Multiyear Software Leases Target Higher Margins
The company structures commercial agreements as minimum three-year terms pairing device access with recurring software subscriptions. Management expects commercial sales to deliver higher margins than its development work as the installed base expands.
Our commercial model pairs device purchases or leases with recurring software and service revenue under agreements with a minimum 3-year term…
— David McGuire, Chief Financial Officer
Looking Ahead
Routine burn care represents the primary commercial expansion target beyond mass-casualty preparedness. Clinical validation and hospital procurement progress drive management’s commercial strategy.
While preparedness remains an important component of our strategy, we believe the much greater opportunity is to make this technology available as part of the clinical protocol for everyday burn care.
— Vincent Stanley Capone, Chief Executive Officer
Long-term growth depends on expanding the U.S. hospital footprint, securing higher reimbursement, and building recurring subscription revenue.
Our focus is on delivering for our initial customers, learning from each deployment, and establishing the process that can support a broader adoption across the United States.
— Vincent Stanley Capone, Chief Executive Officer
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 768%* — a market-crushing outperformance compared to 199% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of November 21, 2026.